RecGBM are frequently treated with bevacizumab, an anti-angiogenic drug that targets the VEGF-VEGFR axis with the aim of disrupting tumor angiogenesis; however, survival benefits with this monotherapy are negligible [29]. The gene discussed is VEGFA; the disease is neoplasm.